Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates

Int J Cancer. 2000 May 15;86(4):582-9. doi: 10.1002/(sici)1097-0215(20000515)86:4<582::aid-ijc22>3.0.co;2-i.

Abstract

Three chimeric proteins were obtained by fusing together the dianthin gene and DNA fragments encoding for the following membrane-acting peptides: the N-terminus of protein G of the vesicular stomatitis virus (KFT25), the N terminus of the HA2 hemagglutinin of influenza virus (pHA2), and a membrane-acting peptide (pJVE). Chimeric dianthins (KFT25DIA, pHA2DIA and pJVEDIA) retained full enzymatic activity in cell-free assays and showed increased ability to induce pH-dependent calcein release from large unilamellar vesicles (LUVs). pHA2DIA and pJVEDIA also showed faster kinetics of interaction with LUVs, while KFT25DIA and pHA2DIA displayed a reduced cytotoxicity as compared to wild-type dianthin. Conjugates made by chemically cross-linking KFT25DIA or pJVEDIA and human transferrin (Tfn) showed greater cell-killing efficiency than conjugates of Tfn and wild-type dianthin. As a consequence, by fusion of membrane-acting peptides to the dianthin sequence the specificity factor (i.e., the ratio between non-specific and specific toxicity) of Tfn-KFT25DIA, Tfn-pHA2DIA and Tfn-pJVEDIA was increased with respect to that of Tfn-based conjugates made with wild-type dianthin. Taken together, our results suggest that genetic fusion of membrane-acting peptides to enzymatic cytotoxins results in the acquisition of new physico-chemical properties exploitable for designing new recombinant cytotoxins and to tackle cell-intoxication mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Hydrogen-Ion Concentration
  • Immunotoxins / pharmacology*
  • Jurkat Cells
  • Lipid Bilayers*
  • Membranes, Artificial
  • Monensin / pharmacology
  • Plant Proteins / pharmacology*
  • Recombinant Fusion Proteins / pharmacology*
  • Ribosome Inactivating Proteins, Type 1
  • Transferrin / pharmacology*

Substances

  • Immunotoxins
  • Lipid Bilayers
  • Membranes, Artificial
  • Plant Proteins
  • Recombinant Fusion Proteins
  • Ribosome Inactivating Proteins, Type 1
  • Transferrin
  • Monensin